The influence of iloprost on acute lung injury induced by hind limb ischemia-reperfusion in rats.
The local ischemia-reperfusion (I/R) process gains a systemic nature and affects distal organs. The remote effects of I/R are most frequently observed in the lungs and pulmonary damage may vary from acute lung injury with mild dysfunction to severe respiratory failure or the acute respiratory distress syndrome. In this hind limb I/R induced experimental lung injury model two groups of rats as IR and ILO were determined. Both groups underwent 60 min of ischemia and 120 min of reperfusion. While ILO group received iloprost in saline, IR group received only saline before reperfusion period intravenously. Serum myeloperoxidase (MPO) activity, malondialdehyde (MDA) levels and total antioxidant capacity (TAC) and lung tissue MPO activity, MDA levels and Na+-K+ ATPase activity were measured and light microscopic analyses of lung specimens were performed. The MPO activities in serum and lung homogenates were found to be significantly decreased in ILO group (P < or = 0.01). The MDA levels in lung homogenates were found to be significantly decreased in ILO group (P < or = 0.01), but the decreases were not significant in serum MDA levels (P=0.052). Serum TAC and lung tissue Na+-K+ ATPase activity levels were found to be increased in ILO group compared to IR group (P < or = 0.01). Lung histology showed marked improvement by iloprost compared to the IR group in this study. Iloprost has been found to be effective in attenuating ischemia reperfusion-induced remote organ damage, in this case, lung injury, in rats.
Koksel
Oguz
O
Department of Thoracic Surgery, Mersin University, School of Medicine, Mersin, Turkey. oguzkoksel@mersin.edu.tr
Ozdulger
Ali
A
Aytacoglu
Barlas
B
Tamer
Lulufer
L
Polat
Ayse
A
Sucu
Nehir
N
Yildirim
Caglar
C
Degirmenci
Ulas
U
Kanik
Arzu
A
D000208:Acute Disease; D000251:Adenosine Triphosphatases / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D027682:Cation Transport Proteins / Q000378:metabolism; D006614:Hindlimb / Q000098:blood supply / Q000503:physiopathology*; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008315:Malondialdehyde / Q000097:blood / Q000378:metabolism; D020556:Neutrophil Infiltration / Q000187:drug effects; D009195:Peroxidase / Q000097:blood / Q000378:metabolism; D011650:Pulmonary Alveoli / Q000378:metabolism / Q000473:pathology; D011654:Pulmonary Edema / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000150:complications / Q000503:physiopathology*; D012131:Respiratory Insufficiency / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D000254:Sodium-Potassium-Exchanging ATPase; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use
D000975:Antioxidants; D027682:Cation Transport Proteins; D014665:Vasodilator Agents; D008315:Malondialdehyde; D009195:Peroxidase; D000251:Adenosine Triphosphatases; C022761:potassium transporting ATPase; C021838:sodium-translocating ATPase; D000254:Sodium-Potassium-Exchanging ATPase; D016285:Iloprost